Zymeworks Authorizes $200 Million Share Repurchase Program
Zymeworks (ZYME) has announced that its board of directors has authorized a second share repurchase program for 2026, with a total potential value of up to $200 million. The company expects to execute approximately $140 million of these buybacks through the year 2028. The company plans to initiate the repurchases before the end of 2026, contingent upon the completion of its current strategic objectives. This move signals management's confidence in the company's long-term value and capital allocation strategy.

Topics: board authorization capital allocation share repurchase
Read the full article at Seeking Alpha
Part of the story China Automotive Systems Reports Record Q3 2026 EPS Unit Sales and $5 Million Share Repurchase Program (7 articles)